Cover Image

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer

Abiraterone acetate (AA) is the first-in-class of drugs belonging to the second-generation of agents inhibiting androgen neosynthesis in advanced prostate cancer. A cumulative experience attests that germinal gene polymorphisms may play a role in the prediction of anticancer agent pharmacodynamics v...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jean-Marc Ferrero (Author), Hakim Mahammedi (Author), Gwenaelle Gravis (Author), Guilhem Roubaud (Author), Philippe Beuzeboc (Author), Remi Largillier (Author), Delphine Borchiellini (Author), Claude Linassier (Author), Nathalie Ebran (Author), Tanguy Pace-Loscos (Author), Marie-Christine E (Author), Renaud Schiappa (Author), Jocelyn Gal (Author), Gérard Milano (Author)
Format:	Book
Published:	MDPI AG, 2023-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
by: Yi-Ting Lin, et al.
Published: (2021)

A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients
by: Bertalan Fekete, et al.
Published: (2023)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017)

Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer
by: Shota Torii, et al.
Published: (2024)

Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Xin Wang, et al.
Published: (2020)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017)

Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients
by: Wu X, et al.
Published: (2020)

Animal Castration
by: Liautard, Alexandre François Augustin, 1835-1918

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
by: Ming-kun Chen, et al.
Published: (2022)

Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis
by: Xiaolei Zhu, et al.
Published: (2019)

Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
by: Xiaolei Zhu, et al.
Published: (2019)

Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective
by: Ivana Z. Kuzminac, et al.
Published: (2024)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018)

Abiraterone Acetate Complexes with Biometals: Synthesis, Characterization in Solid and Solution, and the Nature of Chemical Bonding
by: Petr Buikin, et al.
Published: (2023)

Response and Resistance in Castration-Resistant Prostate Cancer
Published: (2020)

Acute Cold / Restraint Stress in Castrated Rats
by: Farideh Zafari Zangeneh, et al.
Published: (2008)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone
by: Cristian Lolli, et al.
Published: (2016)

Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies
by: Marlies Braeckmans, et al.
Published: (2022)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015)

Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol<sup>®</sup> Enabled Amorphous Solid Dispersions
by: Urvi Gala, et al.
Published: (2020)

Effect of Castration on Some Physiological Aspect in Rats: Effect of Testosterone Hormone
by: A. A. Hassan
Published: (2010)

Changes of electrocardiograms of animals with epinephrine heart damage in influences of stress and castration
by: R. Druziuk, et al.
Published: (2023)

Prediction of severe post-castration syndrome in women after surgical menopause
by: L.I. Butina, et al.
Published: (2022)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
by: Brandon Bumbaca, et al.
Published: (2018)

Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
by: Faiza Naseer, et al.
Published: (2021)

Very Early PSA Response to Abiraterone in mCRPC Patients: a Novel Prognostic Factor Predicting Overall Survival
by: Gaetano eFacchini, et al.
Published: (2016)

Comparison of clinical-economic evaluation of cabazitaxel and abiraterone for prostate cancer based on the results of clinical trials and real world data
by: A. S. Kolbin, et al.
Published: (2018)

Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation
by: Yuanfen Liu, et al.
Published: (2022)

The Transgender Exigency Defining Sex and Gender in the 21st Century
by: Schiappa, Edward
Published: (2022)

The Transgender Exigency Defining Sex and Gender in the 21st Century
by: Schiappa, Edward
Published: (2022)

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
by: Rajae Touzani, et al.
Published: (2019)

Pharmacokinetic Variability in Pre-Clinical Studies: Sample Study with Abiraterone in Rats and Implications for Short-Term Comparative Pharmacokinetic Study Designs
by: Jana Královičová, et al.
Published: (2022)

Clinical and morphological features of post-castration syndrome in women after surgical menopause
by: L.I. Butina, et al.
Published: (2022)

Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer
by: Meenakshi Meenu, MBBS, MD, DM, et al.
Published: (2020)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
by: Bretoni A, et al.
Published: (2019)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
by: Channing J Paller, et al.
Published: (2011)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
by: Bretoni A, et al.
Published: (2019)